Pay in 4 interest-free payments of $5.88 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Regulatory Status in 2026 BPC-157 has no FDA approval for human therapeutic use in the United States and is not eligible for compounding under 503B rules
Physiol Rev 87(4):14091439 Kieffer TJ, McIntosh CH, Pederson RA (1995) Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV
Our evaluation is designed to identify any of these concerns before treatment begins
Inject in the morning if drinking that evening
Additional Information & Research Details COA & Canadian Third-Party Testing Independent, verifiable Canadian third-party testing All third-party testing conducted by Integrity Peptides is performed through independent Canadian analytical laboratories
US$ 24.01
US$ 29.37
US$ 29.49
